Hints and tips:
Showing results for ZIMMER BIOMET U.S., INC.
Related Special Reports
...The advisory board on the beta stage are law firm Orrick, Google, medical device company Zimmer Biomet, insurance group Marsh McLennan and media business Hearst....
...Of the large-cap health stocks, Vermeer Partners, another London-based wealth manager, favours medical device stocks Zimmer Biomet and Smith & Nephew, given that demand for elective surgery has been deferred...
...Zimmer Biomet, which makes artificial joints and dental devices, saw its shares tumble to their lowest point since April after it lowered its 2016 outlook due to supply chain problems that dragged on its...
...Zimmer and Biomet will cut costs by merging, he admits, but adds: “Will they grow their top line? I bet it doesn’t work.”...
...This is, in large part, why Zimmer’s decision to buy privately owned rival Biomet, announced on Tuesday, makes such good sense....
...Zimmer shareholders will own 84 per cent of the combined company, with Biomet shareholders owning 16 per cent....
...Recent deals among medical device makers include Zimmer/Biomet and Medtronic/Covidien (the latter is also a so-called tax inversion). And so tax-driven healthcare deals have not emerged from a vacuum....
...The Medtronic deal is the second big takeover in the sector this year after the $13bn acquisition of Biomet by Zimmer in April to create the world’s biggest maker of hip and knee implants....
...Continued deal activity lifted shares of several device makers following Zimmer Holdings’ purchase of rival Biomet for $13.4bn....
...Mr Bohuon’s comments come a week after Indiana-based Zimmer, maker of the eponymous walking frame, agreed to buy orthopaedic products group Biomet for $13bn....
...Another US rival Zimmer, the maker of joint replacement technology, acquired Biomet in a blockbuster deal worth $13.4bn....
...As well as Pfizer’s abortive $116bn attempt to take over UK rival AstraZeneca, there have been deals between Zimmer and Biomet, and Novartis and GSK....
...On Thursday, a group including KKR, along with Blackstone, the private equity arm of Goldman and TPG announced they had sold Biomet, a deal done in the peak years to Zimmer for $13bn....
...US drugmaker Mylan launched a fresh $9bn bid for Sweden’s Meda and Zimmer agreed to acquire rival medical products maker Biomet for $13.4bn....
...The network was one of several unearthed during a probe by the US in 2007 into corruption by medical device groups in Greece, with probes continuing against rivals including Biomet, Stryker, Zimmer and Medtronic...
...The question, however, is not whether Biomet wants S&N, but whether it can afford it....
...The list of realistic bidders for S&N is limited to a handful of US groups: Biomet, Johnson & Johnson, Zimmer and Stryker....
...Biomet, a private equity rival, has been touted as a potential merger partner for S&N in recent weeks....
...A combination with Biomet, the Indiana-based producer of replacement hips, knees and shoulders which was taken private in 2006 by Blackstone, Goldman Sachs, KKR and TPG, is a possibility....
...Other competitors such as Stryker and Zimmer may also be interested in a bid....
...It would become the world number two in hip and knee reconstruction (c23% market share, after Zimmer with 24%) and number three in Trauma, with a 13% market share (after Synthes with 50% and Stryker, with...
...The press release: In response to market speculation, Synthes, Inc....
...One theory was that Biomet, its US rival, may be in the early stages of investigating a takeover approach....
...Cazenove saw US peer Biomet as the only likely trade buyer. However. Biomet was taken private at the top of the market and is burdened with too much debt, the broker said....
...In the case, Zimmer and four other companies – Depuy, Biomet, Stryker of the US and Smith & Nephew of the UK – were accused of paying large sums of money to surgeons as well as giving them trips and expensive...
International Edition